Sanofi SA reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Sales increased 6% year over year, up 10.1% in constant currency, driven by growth in Immunology, pharmaceutical launches and Beyfortus.

The French drug maker reported that in the second quarter of 2025, business operating income reached € 2.46 billion, down 2.4% year over year, and up 3% in constant currency.

First-half operating income jumped to €5.36 billion, up 8.6% (+10.8%).

The reported adjusted EPS of 1.59 euros or 90 cents per ADS, missing the consensus of 96 cents, up 1.9% (+8.3% on constant currency).

Pharma launches increased sales by 39.8%, reaching € 897 million, driven by ALTUVIIIO sales of €291 million, up 91.8% at constant currency.

Dupixent sales increased by 21.1% to 3.83 billion Euros, supported by the launch of COPD.

Also Read:  Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

Vaccine sales reached €1.21 billion, representing a 10.3% increase, primarily driven by the geographic rollout of Beyfortus infant protection.

Beyfortus sales were €72 million, up 322.2% at CER.

Polio/Pertussis/Hib (PPH) primary and booster vaccine sales were 693 million euros, an increase of 1.3%, driven by demand for pediatric combinations in the Rest of the World.

Paul Hudson, Sanofi ( SNY ) CEO, said, "We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range”

Guidance: Sanofi ( SNY ) ups 2025 sales growth guidance to high single digits at CER from mid-to-high single-digit range.

The company plans to complete a €5 billion share buyback in 2025, 80.3% has already been repurchased.

In July, Sanofi ( SNY ) agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K., for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements.

The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses. It expands vaccine design and development capabilities with Vicebio's ‘Molecular Clamp' technology.

Sanofi ( SNY ) announced its plans to invest at least $20 billion in the U.S. through 2030 in May. Most of the spending will be allocated to research and development, as well as U.S. manufacturing.

Price Action: SNY stock is down 6.36% at $46.12 during the premarket session at the last check on Thursday.

Read Next:

California’s $21B Wildfire Fund Faces Existential Test As Edison Liability Looms: ‘Claims May Be Substantial Enough To Fully Exhaust The Fund’